HC Wainwright Forecasts Higher Earnings for ADMA Biologics

ADMA Biologics, Inc. (NASDAQ:ADMA) – Investment analysts at HC Wainwright boosted their FY2024 EPS estimates for ADMA Biologics in a report issued on Friday, November 8th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will earn $0.55 per share for the year, up from their prior forecast of $0.49. HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.49 per share. HC Wainwright also issued estimates for ADMA Biologics’ Q4 2024 earnings at $0.19 EPS, Q1 2025 earnings at $0.20 EPS, Q2 2025 earnings at $0.21 EPS, Q3 2025 earnings at $0.22 EPS and Q4 2025 earnings at $0.24 EPS.

ADMA has been the topic of a number of other reports. Raymond James raised their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th.

ADMA Biologics Trading Up 14.7 %

ADMA opened at $22.62 on Monday. The company’s 50 day moving average is $18.12 and its 200-day moving average is $13.95. ADMA Biologics has a 1-year low of $3.60 and a 1-year high of $23.52. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. The company has a market cap of $5.27 billion, a P/E ratio of 161.57 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The company had revenue of $107.20 million for the quarter, compared to the consensus estimate of $86.44 million. During the same period last year, the company posted ($0.02) EPS. The firm’s quarterly revenue was up 78.4% compared to the same quarter last year.

Insider Buying and Selling at ADMA Biologics

In other news, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now owns 2,059,726 shares in the company, valued at $36,436,552.94. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares in the company, valued at approximately $2,843,290.27. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. LSV Asset Management bought a new position in ADMA Biologics during the first quarter valued at approximately $1,028,000. Sei Investments Co. grew its position in ADMA Biologics by 176.0% during the first quarter. Sei Investments Co. now owns 393,481 shares of the biotechnology company’s stock valued at $2,597,000 after acquiring an additional 250,925 shares during the last quarter. Inspire Investing LLC grew its position in ADMA Biologics by 125.2% during the first quarter. Inspire Investing LLC now owns 189,303 shares of the biotechnology company’s stock valued at $1,249,000 after acquiring an additional 105,256 shares during the last quarter. Russell Investments Group Ltd. grew its position in ADMA Biologics by 90.7% during the first quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock valued at $7,717,000 after acquiring an additional 556,175 shares during the last quarter. Finally, ProShare Advisors LLC grew its holdings in shares of ADMA Biologics by 9.2% in the first quarter. ProShare Advisors LLC now owns 54,293 shares of the biotechnology company’s stock worth $358,000 after purchasing an additional 4,570 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.